linjc16/ctgov huggingface dataset:
Recognize High Pressure Areas in Human Body to Prevent Decubitus Ulcers

Study Overview
=================
Brief Summary
-----------------
Prolonged external pressure to the tissue leads to compression, ischemia and development of pressure ulcer. Underweight seems to be associated with high pressure ulcer risk but the distinct relation between overweight and pressure ulcer development is uncertain. Bedsores are caused by pressure against the skin that limits blood flow to the skin and nearby tissue. Others factors related to limited mobility can make the skin vulnerable to damage and contribute to the development of pressure sores. Three primary contributing factors are sustained pressure, friction and shear. Bedsores are easier to prevent than to treat.

Detailed Description
-----------------
age weight high BMI pressure scanning map Alimentary status Diseases

Official Title
-----------------
Mapping Pressure of Human Body to Prevent Bedsores

Conditions
-----------------
Pressure Ulcer Stage 1

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient admitted for elective surgery, Patients above 18 y.o., Patient admitted for surgery that required 3 or more days in hospital Exclusion Criteria: Patients under 18 Patients that require emergency surgery Patients that have bedsores before admission

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| BMI 20 to 24.99<br>30 patients | |
| BMI 25 to 29.99<br>30 patients | |
| BMI 30 to 34.99<br>30 patients | |
| BMI 35 to 39.99<br>30 patients | |
| BMI 40 to 44.99<br>30 patients | |
| BMI 45 to 49.99<br>30 patients | |
| BMI more than 50<br>30 patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mapping body pressure | The patient need to rest above a mattress with sensors for pressure and the data is obtained by an specific software | up to 6 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
BMI, Pressure, Bedsore
Androcur Effects on Quality of Life

Study Overview
=================
Brief Summary
-----------------
Androcur is an antiandrogenic drug, which blocks the action of male sex hormones. Androcur is used for treatment of advanced prostate cancer. This study investigates the effect of Androcur on quality of life of prostate cancer patients who are taking the drug for 12 months

Official Title
-----------------
Measure of Androcur Effects on Quality of Life at Prostate Cancer Patients

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Drug: Cyproterone acetate (Androcur)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed adenocarcinoma of the prostate Inoperable prostate tumor or progradiated after surgery/ irradiation therapy Locally advanced tumor or distant metastases is present Exclusion Criteria: Patient not fulfil the recruitment criteria Liver disease; Dubin-Johnson syndrome; Rotor syndrome; previous or existing liver tumours (in carcinoma of the prostate only if these are not due to metastases); wasting diseases (with the exception of carcinoma of the prostate); depression; previous or existing thromboembolic processes; diabetes with vascular changes; sickle-cell anaemia. As regards patients with prostatic carcinoma who have a history of thromboembolic processes and/or an existing sickle-cell anaemia, or diabetes with vascular changes, the risk:benefit ratio must be considered carefully in each individual case before the use of Androcur

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Cyproterone acetate (Androcur)<br>* The study drug will be administered either as monotherapy or in combination with other interventions (surgical castration or LHRH analogue treatment). Daily dosage as monotherapy: 200-300 mg cyproterone acetate. Daily dosage following surgical castration: 100-200 mg cyproterone acetate. Daily dosage in combination with an LHRH-analogue: 100-200 mg cyproterone acetate. Administration period: 12 months.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life change measured by SF-35 questionnaire |  | Baseline, after 3, 6 and 12 month |
Intelligent Cataract Screening With Portable Slit-lamp

Study Overview
=================
Brief Summary
-----------------
Based on the portable slit-lamp connected to the smartphone, the artificial intelligence machine learning algorithm is used to establish a cataract screening model by prospectively collecting the anterior segment photographic data, and a portable slit lamp intelligent screening referral model based on the smartphone connection is also established.

Official Title
-----------------
Intelligent Cataract Screening With Portable Slit-lamp

Conditions
-----------------
Catarct Screening, Artificial Intelligence

Intervention / Treatment
-----------------
* Device: Portable slit-lamp photography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 0 to 100 years old Exclusion Criteria: (1) History of eye disease except for age-related cataracts (2) History of eye trauma or eye surgery (3) Unable to cooperate with ophthalmology and general examination (4) Individuals with incomplete information (5) Unwilling to participate in this study

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Referral group<br>The patients with severe cataracts in this group need a referral to a higher-level hospital for further treatment. | Device: Portable slit-lamp photography<br>* The enrolled patients will undergo portable slit-lamp photography with and without mydriasis and receive traditional slit-lamp photography for comparison.<br>|
| Observation group<br>The patients with mild cataracts or transparent lenses in this group do not need a referral to a higher-level hospital for further treatment and keep regular examinations. | Device: Portable slit-lamp photography<br>* The enrolled patients will undergo portable slit-lamp photography with and without mydriasis and receive traditional slit-lamp photography for comparison.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The accuracy of referral | The accuracy of referral of AI model will be calculated with the decisions based on the portable slit-lamp images with reference to the ground truth. | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The accuracy of cataract diagnosis | The accuracy of cataract diagnosis of AI model will be calculated with the decisions based on the portable slit-lamp images with reference to the ground truth. | Baseline |
Receiving Genetic Information: A Quantitative Survey

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the public's response to receiving genetic information via an electronic platform. It will comprise of an internet run quantitative survey.

Detailed Description
-----------------
There is currently a high prevalence of obesity in the UK. Diets personalised to an individual's genetics could help to reduce the prevalence. However, how the public will respond to this information is unknown. The use of technology is very common and could provide an accessible platform to communicate genetic results to the public. Therefore, this study will evaluate the public's response to receiving genetic information via an electronic platform. This study will comprise of an internet run quantitative survey. The survey will be circulated using relevant websites, internet forums, emails and social media. Participants will be required to complete the survey once which will take around 10 minutes. The participants will not be required to complete the survey in a controlled setting, it may be complete wherever the participant feels comfortable. Data analysis will take place at St Mary's University.

Official Title
-----------------
The Public's Response to Receiving Genetic Information Via an Electronic Platform: A Quantitative Survey

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Other: Survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: UK citizens between the ages of 18 and 65 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Whole Cohort<br>UK Citizens, aged 18-65 years | Other: Survey<br>* Survey<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BMI against response. | If BMI and socioeconomic status differs between participants who show a positive response to receiving genetic information to those that show a negative response. | October - November 2018 | 
| Socioeconomic status versus response. | If socioeconomic status and socioeconomic status differs between participants who show a positive response to receiving genetic information to those that show a negative response. | October - November 2018 |
Extended Spectrum Betalactamase Producing Bacteria; Epidemiology and Treatment in Non-hospitalized Patients

Study Overview
=================
Brief Summary
-----------------
This project aims at investigating the duration of human fecal carriage of bacteria harboring plasmid-borne resistance genes expressing Extended Spectrum beta-lactamases (ESBL), risk factors for infections with such bacteria and persistence, mobility and spread of ESBL in the environment and within households. It also aims to compare different methods of detecting ESBL carriage and treat patients with urinary tract infection caused by these bacteria.

Official Title
-----------------
Extended Spectrum Beta-lactamases - Treatment, Carriage, Environmental Dissemination And Population Epidemiology

Conditions
-----------------
Urinary Tract Infection, Infection Due to ESBL Bacteria, Environmental Contamination of ESBL

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients >=18 of age with a urine culture yielding E. coli or K. pneumoniae >10.000 colony forming units/mL. Exclusion Criteria: Patients who have lived in Norway for <1 year Patients who are unable to answer a questionaire Patients who have been infected with an ESBL producing bacteria before Patients who have been admitted to a hospital or a long term care facility for >24 hours during the past 31 days.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment Failure | Patients included in the study with urinary tract infection (UTI) and treated as part of normal routine were followed for 14 days and further prescriptions of antimicrobials normally used for treatment of UTI will be considered treatment failures. Only participants that received pivmecillinam are reported here. In the paper published in PlosOne High Rate of Per Oral Mecillinam Treatment Failure in Community-Acquired Urinary Tract Infections Caused by ESBL-Producing Escherichia coli the mecillinam treatment group were compared with the group that did not receive mecillinam. | 14 days after initiation of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjective Outcome | A patient form will be filled in. Data about cessation of symptoms of urinary tract infection will be recorded. | 14 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ESBL, treatment, carriage, risk factors, water contamination, Urinary tract infection
Nitrate-based Nutritional Formula for Oxygen Saturation and Patient-reported Outcomes in Covid-19

Study Overview
=================
Brief Summary
-----------------
A preliminary open-label case report demonstrated the beneficial effects of an innovative nitrate-based nutritional formula on oxygen saturation in patients with COVID-19. Whether these initial findings are relevant in a more robust research design currently remains unknown. Therefore, the main objective of this randomized controlled trial was to analyze the acute effects of nitrate-based nutritional formula on peripheral SpO2, patient-reported outcomes, and safety indices in patients with acute COVID-19 infection.

Official Title
-----------------
Short-term Intervention With Nitrate-based Nutritional Formula on Oxygen Saturation and Patient-reported Outcomes in Covid-19 Patients

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Dietary Supplement: NITRATE
* Dietary Supplement: PLACEBO


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 3 18 years confirmed SARS-CoV-2 infection SpO2 < 95% COVID-19 patients in stable condition (i.e., not requiring hospital admission) Exclusion Criteria: regnant or lactating women concomitant pulmonary and cardiovascular conditions history of dietary supplement use during the past four weeks participation in another COVID-19-related study unwillingness to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: NITRATE<br>Multi-component nutritional formula (containing 1200 mg of potassium nitrate, 200 mg of magnesium, 50 mg of zinc, and 1000 mg of citric acid) | Dietary Supplement: NITRATE<br>* Multi-component nutritional formula<br>|
| Placebo Comparator: PLACEBO<br>Placebo (2.5 grams of inulin) | Dietary Supplement: PLACEBO<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in oxygen saturation | Measured at baseline and 72 hours post-intervention | Baseline vs. 72 hours post-intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in fatigue | Measured at baseline and 72 hours post-intervention | Baseline vs. 72 hours post-intervention |
Preeclampsia and Circulating Biomarkers

Study Overview
=================
Brief Summary
-----------------
In order to assess circulating biomarkers of cardiovascular risk, we will conduct a 10-year follow-up study comparing 32 exposed (women with a history of pregnancy complicated by preeclampsia) and 32 unexposed (women with a history of uncomplicated pregnancy). Participants will be recruited from a well-characterised cohort, previously assembled during their pregnancies, at the Department of Obstetrics at Randers Regional Hospital in 2001-2004. Blood and urine samples, collected during their pregnancies, are stored in a biobank, thus rendering the possibility of longitudinal assessment.

Conditions
-----------------
Postpartum CVD Risk in Women With Previous Preeclampsia.

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participation in previous study 2001-2005. Exclusion Criteria: Current pregnancy or breastfeeding
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Exposed<br>Women with a history of preeclampsia 10 years ago | |
| Unexposed<br>Women with a history of uncomplicated pregnancy 10 years ago | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Circulating biomarkers of cardiovascular disease 10 years postpartum. |  | 10 years postpartum | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Markers of arteriosclerosis and atherosclerosis |  | 10 years postpartum | 
| Circulating biomarkers of cardiovascular disease at baseline pregnancy. |  | During pregnancy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Preeclampsia, Cardiovascular disease (CVD) risk
Virtual Reality-based Exercise in Older Adults

Study Overview
=================
Brief Summary
-----------------
The aim of the present study is to evaluate an innovative virtual reality-based balance training intervention for improving clinically relevant motor performances (balance and gait) in older adults. We hypothesize that the virtual reality-based balance training intervention will improve balance and gait performances in older adults compared to a control group receiving usual care only.

Official Title
-----------------
Promoting Virtual Reality-based Exercise to Prevent Falls in Older Adults: Pilot Study

Conditions
-----------------
Distorted; Balance, Motor Deficit

Intervention / Treatment
-----------------
* Other: Balance Training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ability to ambulate without assistance willingness to provide informed consent Exclusion Criteria: severe neurologic, cardiovascular, metabolic, or psychiatric disorders severe visual impairment cognitive impairment

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Balance Training<br>Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes. | Other: Balance Training<br>* Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes.<br>|
| No Intervention: Control<br>The control group will keep their normal activity without receiving any intervention. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postural Balance | Postural Balance during quiet standing for 30 seconds will be assessed using validated wearable sensor technologies (BalanSens™) | after 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gait performance | Gait performance will be measured using validated wearable sensor technology (LEGSys™) | 4 weeks | 
| Cognitive status | Changes in cognitive status will be measured by the Trail Making Test and the Category Fluency Test | 4 weeks | 
| Quality of life |  | 4 weeks | 
| Functional performance | Functional performance will be assessed using the Timed Up and Go Test and the Alternate Step Test | 4 weeks |
Effect of Child Delivery on Intraocular Pressure

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effect of child delivery on the intraocular pressure in healthy women.

Detailed Description
-----------------
Little is known about the changes in intraocular pressure (IOP) during child delivery. During labor there are several stages which are accompanied by many physiological changes and pharmacological interventions that may potentially influence the IOP. Among these are delivery position (lying versus sitting or kneeling), vascular changes and pharmacological effects (anesthetic agents, oxytocin and other drugs). The purpose of this study is to evaluate the effect of child delivery on the intraocular pressure (IOP) in healthy women. This will expend our understanding of the physiology of labor and its effect on the eye and it may serve as basis to determine the management of labor.

Official Title
-----------------
The Effect of Child Delivery on the Intraocular Pressure

Conditions
-----------------
Intraocular Pressure, Delivery, Obstetric

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years. Pregnant women admitted to the labor room. Healthy women that do not take any systemic medications. No known ocular condition, except for refraction errors, strabismus or amblyopia. Eligible women who are able to sign an informed consent form. Exclusion Criteria: Family history of glaucoma (first degree relatives). Known allergic reaction to local anesthesia (oxybuprocaine hydrochloride). Women who are unable to sign an informed consent form.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pregnant women<br>Healthy pregnant women | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraocular Pressure | Intraocular pressure during different stages of child delivery. | During child delivery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intraocular pressure, Ocular tonometry, Obstetric delivery